Ivabradin Heumann (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. This inhibition reduces the rate of spontaneous depolarisation, leading to a slower heart rate while leaving contractility and blood pressure largely unchanged, which is useful in angina and certain heart‑failure states.

The exact dose of Ivabradin Heumann is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Physicians typically start with a low dose and titrate upward as needed, following local prescribing guidelines and monitoring parameters.

Safety data for ivabradine during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare professional should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to ivabradine for heart‑rate reduction is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or not tolerated. However, beta‑blockers also provide anti‑ischemic and anti‑arrhythmic benefits that ivabradine does not.

Store Ivabradin Heumann at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use to maintain product stability.

Ivabradin Heumann is administered orally as a tablet. It can be taken with or without food, but patients should follow the prescribing physician’s instructions regarding timing relative to meals to ensure consistent absorption.

The most serious risks include severe bradycardia that may cause dizziness or syncope, atrial fibrillation or other arrhythmias, and rare visual disturbances such as persistent loss of vision. Patients should report any episodes of fainting, rapid irregular heartbeats, or new visual symptoms to their healthcare provider promptly.

Ivabradin Heumann should be avoided in patients with a resting heart rate below 60 bpm, those with sick‑sinus syndrome, acute decompensated heart failure, severe hypotension, or known hypersensitivity to ivabradine or any excipients. It is also contraindicated in combination with certain strong CYP3A4 inhibitors.